LONDEN–(BUSINESS WIRE)–Het Britse regtech-bedrijf SPORVIGILANCE richt zich op een van de grootste nalevingsuitdagingen van de farmaceutische sector met een platform dat een snellere route biedt naar IDMP- en SPOR-paraatheid, naleving en beheer. Nu de EMA (European Medicines Agency) gestructureerde gegevens over geneesmiddelen vooropstelt, komen bedrijven onder druk om regulatorische gegevens nauwkeurig, gestandaardiseerd en conform met EMA-vereisten te houden. SPORVIGILANCE vervangt gefragmen
Month: September 2026
LONDON–(BUSINESS WIRE)–Das britische RegTech-Unternehmen SPORVIGILANCE nimmt eine der größten Compliance-Herausforderungen der globalen Pharmaindustrie ins Visier – mit einer Plattform, die einen schnelleren Weg zur IDMP- und SPOR-Bereitschaft, Compliance und Governance bietet. Da die Europäische Arzneimittelagentur (EMA) strukturierte Arzneimitteldaten vorantreibt, stehen Unternehmen unter dem Druck, regulatorische Daten korrekt, standardisiert und im Einklang mit den EMA-Anforderungen zu ha
LONDRES–(BUSINESS WIRE)–L’entreprise britannique de technologie réglementaire SPORVIGILANCE s’attaque à l’un des principaux défis de conformité de l’industrie pharmaceutique mondiale grâce à une plateforme permettant d’accélérer la préparation, la conformité et la gouvernance de la norme IDMP et des données SPOR. Alors que l’Agence européenne des médicaments fait progresser la structuration des données sur les médicaments, les entreprises sont confrontées à la nécessité de maintenir l’exactit
LONDON–(BUSINESS WIRE)–British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance. As the European Medicines Agency advances structured medicinal product data, companies face pressure to keep regulatory data accurate, standardised and aligned with EMA requirements. SPORVIGILANCE replaces fragmented manual assessment with a regulatory intelligen
LONDRA–(BUSINESS WIRE)–La società britannica specializzata in tecnologia normativa SPORVIGILANCE punta a una delle maggiori sfide di conformità per il settore farmaceutico globale con una piattaforma che offre un percorso più rapido a preparazione, conformità e governance relative all’IDMP e allo SPOR. Man mano che l’Agenzia europea per i medicinali (EMA) porta avanti dati strutturati di prodotti medicinali, le aziende sono soggette a pressioni per mantenere i dati accurati, standardizzati e
LONDRES–(BUSINESS WIRE)–La empresa británica de tecnología regulatoria SPORVIGILANCE apunta a resolver uno de los principales desafíos de cumplimiento normativo de la industria farmacéutica mundial con una plataforma que ofrece una vía más rápida para facilitar la preparación, el cumplimiento y la gobernanza en materia de normas IDMP y SPOR. La Agencia Europea de Medicamentos (EMA) promueve la disponibilidad de los datos estructurados sobre los medicamentos y en ese sentido, las empresas se v
TOKYO–(BUSINESS WIRE)–NTT DOCOMO, INC. announced today the development of a new AI technology, the Dual-view Adaptive Retrieval-augmented Tweedie model, that enables highly accurate predictions even when only limited historical data is available. The model solves the “cold-start problem,” which occurs when AI cannot make reliable predictions or recommendations due to insufficient historical data—for example, when a new service is launched. DOCOMO expects the model to have potential applicatio
28 SEPTEMBER 2026
NORTHERN 2 VCT PLC
TRANSACTION IN OWN SHARES
Northern 2 VCT PLC (“the Company”) announces that on 25 September 2026 it purchased for cancellation under an existing authority granted by shareholders 1,275,232 ordinary shares of 5p each in the market at a price of 52.63p per share, representing approximately 0.48% of the Company’s issued ordinary share capital. There remain 266,589,293 ordinary shares in issue.
In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (the “DTRs”), the Company notifies the market that the capital of the Company consists of 266,589,293 ordinary shares with a nominal value of 5p each. All the ordinary shares have voting rights. The Company does not hold any ordinary shares in treasury. The total number of voting rights in the Company is therefore 266,589,293 (“the Figure”). The Figure may be used by a shareholder or other person as the denominator for the calculations by which they will determine if they are required to notify the voting rights they hold in relation to the Company, or a change to those voting rights, under the DTRs.
Enquiries:
Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430
Website: www.mercia.co.uk/vcts
The contents of the Mercia Asset Management PLC website and the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website) are not incorporated into, nor form part of, this announcement.
28 SEPTEMBER 2026
NORTHERN VENTURE TRUST PLC
TRANSACTION IN OWN SHARES
Northern Venture Trust PLC (“the Company”) announces that on 25 September 2026 it purchased for cancellation under an existing authority granted by shareholders 1,659,577 ordinary shares of 25p each in the market at a price of 55.67p per share, representing approximately 0.64% of the Company’s issued ordinary share capital. There remain 258,557,032 ordinary shares in issue.
In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (the “DTRs”), the Company notifies the market that the capital of the Company consists of 258,557,032 ordinary shares with a nominal value of 25p each. All the ordinary shares have voting rights. The Company does not hold any ordinary shares in treasury. The total number of voting rights in the Company is therefore 258,557,032 (“the Figure”). The Figure may be used by a shareholder or other person as the denominator for the calculations by which they will determine if they are required to notify the voting rights they hold in relation to the Company, or a change to those voting rights, under the DTRs.
Enquiries:
Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430
Website: www.mercia.co.uk/vcts
Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.
Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction
Please find attached the DNO ASA Statement Regarding Final Offer for Capricorn Energy plc of 28 September 2026.
–
For further information, please contact:
Media: media@dno.no
Investors: investor.relations@dno.no
–
DNO ASA is a Norwegian oil and gas operator active in the North Sea and the Middle East. Founded in 1971, DNO is Norway’s oldest oil company and the first to list on the Oslo Stock Exchange in 1981. The Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in Norway, the Kurdistan region of Iraq, the United Kingdom and Yemen. More information is available at www.dno.no.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Attachment
